PRO MEDICUS LIMITED — Interim / Quarterly Report 2011

Aug 25, 2011

Rule 4.2A

Appendix 4E Preliminary Final Report

1. Company details

Name of entity
	Pro Medicus Limited
ABN or equivalentcompany reference	Financial year ended('current period')	Financial year ended('previous period')
	25 006 194 75230 June 2011	30 June 2010
	2. Results for announcement to the market
ASXListingRulesRef		2011A$'000
2.1	Revenue	14,070
	% change up/(down) of revenue from ordinary activities fromthe previous corresponding period.	Down27.7%
2.2	Profit after tax attributable to members	503
	% change up/(down) of Profit/(Loss) from ordinary activitiesafter tax attributable to members from the previouscorresponding period.	Down87.2%
2.3	Net Profit for the period attributable to members	503
	% change up/(down) of Net Profit/(Loss) for the periodattributable to members from the previous correspondingperiod.	Down87.2%

2.4	Dividends (distributions)	Amount persecurity	Fully Frankedamount persecurity
	Franked dividend amount per security
	Final Dividend	-	-
	Interim dividend	-	-
2.5	Record date for Final dividends		N/A
	Payment date for Final dividends		N/A

2.6	Australia
	The group employs 25 people in Australia who undertake research and development of Pro Medicusproducts as well as sales and service/support functions.
	The group's Australian revenue declined over the period by 41.1% due to slower than anticipatedsales of the Visage 7.0 products and well as a decline in new Radiology Information System (RIS)sales due to the delays in bringing the company's new RIS technology platform to market.
	Promedicus.net, the company's e-health offering, continued to hold its strong market positionrecording revenue of $1.89 million despite increasing competition.
	North America
	The group employs 10 people in North America to fulfil the sales marketing and professional servicesroles. Revenue from North America declined by 14.2% compared to the previous year of which 9%was attributable to currency changes. The company has made a number of changes in the group'sUS operations during the past year including a significant decrease in overall running costs andchanges to management in the 2nd half of the financial year. The company believes these changes willhave a positive impact on the performance of the North American division in the coming years.
	Europe
	Pro Medicus established a presence in Europe with the acquisition of Visage Imaging GmbH in lateJanuary 2009. The group has 41 employees in its Berlin office who undertake research anddevelopment of Visage Imaging products worldwide as well as sales, marketing and service/supportfunctions for the group's European operations.
	Financials
	Full year revenue, declined from $19.46 million to $14.07 million, a decrease of 27.7%.
	Net margin as defined by profit before tax to revenue from operating activities decreased from 32.3%to 5.0% reflecting the decrease in sales of new products and higher development costs.
	Profit after tax for the period was $0.50 million a decrease of 87.2% from the previous year in whatwas a difficult year for the industry. The result was impacted by a decrease in new sales, a number ofone-off termination payments and significant impact from foreign currency exchange rates.
	Shareholder Returns
	The directors are confident that the holdings of reserve cash is sufficient to underpin the developmentand expansion needs of the company as the business looks to increase its penetration of existingmarkets and new product development.
	The company has maintained cash holdings although the return on net assets and equityhas decreased as a result of the acquisition of the Visage Imaging business and lowerprofitability than prior years.
3.	Statement of Comprehensive Income
	Please refer to the Statement of Comprehensive Income in the attached FinancialStatements.
4.	Statement of Financial Position
	Please refer to the Statement of Financial Position in the attached Financial Statements.
5.	Statement of cash flows
	Please refer to the Statement of cash flows in the attached Financial Statements.

6.	Details of Dividends	2011	2010
		$'000	$'000
	Final Dividend
	No Final Dividend (2010: 2.0) per share will be paid.	Nil	$2,005.6
	Current Year Interim
	No interim dividend was paid during 2010-11 (2010: Nil)	-	-
	No foreign sourced dividend or distribution is included in either the interim or finaldividends.
7.	Dividend or Distribution reinvestment plans
	There are no dividend or distribution reinvestment plans in operation.
8.	Statement of Retained Earnings
	Please refer to Statement of Changes in Equity in the attached Financial Statements.
9.	Net Tangible Assets per security	2011	2010
	Net Tangible Assets per security	$0.02	$0.07
10.	Details of entities over which control has been gained or lost during theperiod
	There are no entities over which control has been gained or lost during the period
11.	Associates and joint venture entities
	There are no associates or joint venture entities
12.	Other significant information needed by an investor to make an informedassessment of the entity's financial performance and financial position.Please refer to section 2.6
13.	Foreign Entity accounting standardsAustralian Accounting Standards & International Financial Reporting Standards

14.	Commentary on results for the period.The earnings per security and th e nature of any dilution aspects.Please refer to Note 8 of the attached Financial Statements.
	Returns to shareholders including distributions and buy backs.Please refer to Note 9 of the attached Financial Statements.
	Significant features of operating performance.Please refer to section 2.6.
	The results of segments that are significant to an understanding of the business.Please refer to Note 5 of the attached Financial Statements.
	Discussion of trends in performance.Please refer to section 2.6.
15.	Audit Stateme nt
	This report is based on accounts to which one of the following applies.(Tick one)000The+accountshavebeenThe +accounts have been subject to
	audited .review.
	o0The +accounts have not yet beenThe+accountsaretheinprocess of being audited.audited or reviewed

Sign here Date 26 August 2011

Print name Sam Hupert

Chief Executive Officer

Appendix 4E Page 4